What is the appropriate antibiotic regimen for acute prostatitis in a patient with a urinary tract infection culture growing pan‑sensitive Escherichia coli, a decreasing white‑blood‑cell count, and a stable prostate‑specific antigen of 38.7 ng/mL?

Antibiotic Therapy for Acute Prostatitis with Pan-Sensitive E. coli

For acute prostatitis with pan-sensitive E. coli and improving clinical status (trending down WBC), transition to oral ciprofloxacin 500-750 mg twice daily or levofloxacin 750 mg once daily for a total treatment duration of 14 days, as this represents a complicated UTI in a male patient where prostatitis cannot be excluded. 1

Treatment Rationale

Classification and Duration

Acute prostatitis in males automatically qualifies as a complicated UTI according to the 2024 European Association of Urology guidelines 1. The guidelines explicitly state that treatment for complicated UTIs should be 14 days for men when prostatitis cannot be excluded 1. This is critical because inadequate treatment duration increases recurrence risk.

Antibiotic Selection for Pan-Sensitive E. coli

Since your culture shows pan-sensitive E. coli and the patient is clinically improving (WBC trending down, stable), you can confidently de-escalate to targeted oral therapy:

First-line options:

• Ciprofloxacin 500-750 mg twice daily for 14 days 1
• Levofloxacin 750 mg once daily for 14 days

Alternative if fluoroquinolone contraindicated:

• Trimethoprim-sulfamethoxazole 160/800 mg twice daily for 14 days (if susceptible) 1

Why Fluoroquinolones Are Preferred

The most recent research strongly supports fluoroquinolones for acute bacterial prostatitis. A 2025 comparative study demonstrated that ciprofloxacin achieved 96.9% clinical cure versus 85.7% with cefuroxime, with zero recurrences in the ciprofloxacin group compared to 6.96% with cefuroxime 2. The protective effect was significant (OR: 0.16, p < 0.001) 2.

Fluoroquinolones achieve excellent prostatic tissue penetration with prostate tissue-to-serum ratios ≥ 1, making them superior to most β-lactams which penetrate poorly into non-inflamed prostate tissue 3. This pharmacokinetic advantage translates directly into clinical efficacy 4, 5.

Clinical Considerations

The Stable PSA of 38.7

The elevated PSA (38.7 ng/mL) is expected with acute prostatitis and should not alter antibiotic management. PSA elevation occurs due to prostatic inflammation and disruption of the blood-prostate barrier. Do not pursue prostate cancer workup during acute infection—reassess PSA 4-6 weeks after infection resolution.

Monitoring for Treatment Failure

Watch for these red flags indicating potential treatment failure:

• Persistent fever beyond 72 hours of appropriate therapy 1
• Worsening clinical status (increasing pain, urinary retention, systemic symptoms)
• Prior recent UTI (increases failure risk, OR: 2.87) 2

If fever persists beyond 72 hours or clinical deterioration occurs, obtain imaging (CT or MRI) to exclude prostatic abscess 1, 6.

Treatment Algorithm

For your specific patient:

1. Continue current therapy until afebrile for 48 hours (if currently on IV antibiotics) 1

2. Transition to oral therapy:

   • Ciprofloxacin 500-750 mg PO BID × 14 days total duration, OR
   • Levofloxacin 750 mg PO daily × 14 days total duration

3. Complete full 14-day course even if symptoms resolve earlier 1

4. Reassess PSA 4-6 weeks post-treatment to ensure normalization

5. If symptoms persist or recur: Consider imaging for abscess and extend treatment to 4-6 weeks for possible chronic bacterial prostatitis 5

Common Pitfalls to Avoid

• Don't shorten treatment to 7 days—this is only appropriate for complicated UTIs when prostatitis is definitively excluded, not applicable here 1
• Don't use nitrofurantoin or fosfomycin—insufficient data for efficacy in prostatitis and poor prostatic penetration 1, 3
• Don't use oral cephalosporins as monotherapy—significantly higher recurrence rates (6.96% vs 0% with fluoroquinolones) 2
• Don't pursue cancer workup during active infection—PSA will be falsely elevated

Fluoroquinolone Resistance Considerations

The guidelines recommend fluoroquinolones only when local resistance rates are <10% 1. However, since you have confirmed pan-sensitive E. coli on culture, this concern is moot. The 2024 guidelines also caution against fluoroquinolones if the patient has used them in the last 6 months 1—verify this history.